Pyxis Oncology, Inc.
PYXS
$1.70
$0.010.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 38.61% | -2.96% | -69.27% | -62.64% | -64.75% |
| Total Depreciation and Amortization | 63.73% | 51.27% | -30.69% | -18.74% | -15.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -74.98% | -66.09% | 273.30% | 177.32% | 141.27% |
| Change in Net Operating Assets | 22.29% | 116.43% | -1.34% | 18.35% | 125.20% |
| Cash from Operations | 31.14% | -10.11% | -34.92% | -30.41% | 7.87% |
| Capital Expenditure | -- | 96.20% | 96.20% | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.34% | 601.45% | 961.68% | 817.07% | 251.38% |
| Cash from Investing | 1.32% | 621.73% | 937.00% | 3,508.50% | 277.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -59.14% | -98.75% | -100.00% | -97.15% | -97.17% |
| Repurchase of Common Stock | 98.10% | 98.12% | -2,546.23% | -1,028.65% | -1,100.62% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -67.27% | -99.00% | -100.04% | -97.15% | -97.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 117.51% | -141.30% | -17.98% | -1,640.41% | 39.39% |